Followers | 1107 |
Posts | 28828 |
Boards Moderated | 12 |
Alias Born | 01/11/2016 |

Tuesday, March 19, 2024 8:57:41 PM
Recent LTRN News
- Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer • Business Wire • 01/27/2025 12:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2025 09:05:29 PM
- Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients • Business Wire • 12/09/2024 01:15:00 PM
- Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) • Business Wire • 12/03/2024 01:00:00 PM
- Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality • Business Wire • 11/26/2024 01:45:00 PM
- Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients • Business Wire • 11/19/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 09:07:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 09:05:35 PM
- Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates • Business Wire • 11/07/2024 09:05:00 PM
- Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board • Business Wire • 11/05/2024 01:00:00 PM
- Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET • Business Wire • 10/31/2024 12:00:00 PM
- Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 • Business Wire • 10/23/2024 12:45:00 PM
- Lantern Pharma to Host & Participate in Two Public Webinars During October • Business Wire • 10/21/2024 12:00:00 PM
- Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA • Business Wire • 10/15/2024 01:07:00 PM
- Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers • Business Wire • 09/23/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:07:53 PM
- Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates • Business Wire • 08/08/2024 08:01:00 PM
- Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 • Business Wire • 08/07/2024 01:31:00 PM
- Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort • Business Wire • 08/05/2024 12:00:00 PM
- Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET • Business Wire • 08/01/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:30:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:30:12 PM
- Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 • Business Wire • 07/10/2024 12:30:00 PM
UAV Corp. Expanding in the Global UAV Market, Projected to Exceed $58 Billion by 2027, with Increasing Government and Commercial Sector Adoption • UMAV • Feb 6, 2025 8:30 AM
VAYK Project $700K 2024 Revenue with $150K Net Profit • VAYK • Feb 5, 2025 12:43 PM
UAV Corp (UMAV) Kicks Off Landmark "SKY" Hangar Project with Land Clearing at Costin Airport Setting Stage for Q1 2025 Groundbreaking • UMAV • Feb 5, 2025 8:30 AM
HealthLynked Corp. Releases Annual Shareholder Letter Highlighting Recent Product Development and Strategic Vision for the Future • HLYK • Feb 4, 2025 8:00 AM
Wytec Wins Multi-State Government Contract for AI Gunshot Detection • WYTC • Feb 3, 2025 7:16 AM
UAV Corp. Retains Legal Counsel to Address Legacy Debt from HTTI Era; 500 Million Authorized Shares Confirmed - UAV Corp. Delivers on Strategic Commitments • UMAV • Jan 31, 2025 1:30 PM